title: Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
abstract: We have studied the requirements that have to be met to combine effective cancer chemotherapy with the mobilisation of peripheral blood stem cells (PBSC). We have shown that there is a differential induction of high numbers of PBSC following standard-dose chemotherapy (VIP) plus treatment with colony-stimulating factors. The combined sequential administration of interleukin 3 (IL-3) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) induced maximal numbers of PBSC, including colony-forming unit-granulocyte, erythrocyte, monocyte/macrophage, megakaryocyte (CFU-GEMM) and colony-forming unit-megakaryocyte (CFU-Meg), compared with the application of GM-CSF, granulocyte colony-stimulating factor (G-CSF) or chemotherapy alone. The number of CD34+ cells was highly variable depending on the prior treatment given to the patients. Mobilised CD34+ cells--depending on the cytokines used for recruitment--had a varying cloning efficiency, and were heterogeneous as to their level of commitment. Retransfusion of G-CSF-primed progenitor cells to pilot patients following high-dose chemotherapy demonstrated that PBSC recruited by standard-dose chemotherapy plus G-CSF accelerated both neutrophil and platelet recovery.
authors.affiliation: Department of Medicine I (Haematology/Oncology), Albert-Ludwigs-University Medical Centre, Freiburg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Kanz
authors.forename: W
authors.initials: W
authors.lastname: Brugger
authors.forename: R
authors.initials: R
authors.lastname: Mertelsmann
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001772:Blood Cell Count / Q000187:drug effects; D001804:Blood Transfusion, Autologous; D002945:Cisplatin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005047:Etoposide / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*
chemical_list: D016298:Hematopoietic Cell Growth Factors; D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide